GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a…
Read More »Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in Hong Kong,…
Read More »